<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03743376</url>
  </required_header>
  <id_info>
    <org_study_id>UBP-A209-HIV</org_study_id>
    <nct_id>NCT03743376</nct_id>
  </id_info>
  <brief_title>The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients</brief_title>
  <official_title>The HIV Functional Cure Potential of UB-421: A Phase II, Randomized, Open-label, Controlled, 48 Week, Proof of Concept Study, to Evaluate the Safety of UB-421 in Combination With Standard Antiretroviral Therapy (ART) and the Efficacy of HIV Reservoir Reduction as Compared With ART Alone in ART Stabilized HIV-1 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>United BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taoyuan General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaohsiung Medical University Chung-Ho Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaohsiung Veterans General Hospital.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>United BioPharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluate the safety of UB-421 in combination with standard antiretroviral therapy
      (ART) and the efficacy of HIV reservoir reduction as compared with ART alone in ART
      stabilized HIV-1 patients
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>treatment related TEAEs</measure>
    <time_frame>48Weeks</time_frame>
    <description>the incidence of Grade 3 drug-related treatment-emergent adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the change of immune profiles</measure>
    <time_frame>16Weeks</time_frame>
    <description>Change in Treg percentage in the peripheral blood</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Standard ART</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects will receive standard ART for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UB-421(25mg/kg) Q2W add-on treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UB-421(25 mg/kg) Q2W plus standard ART for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UB-421(25mg/kg) Q4W add-on treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UB-421(25 mg/kg) Q4W plus standard ART for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>UB-421(25 mg/kg) Q2W</intervention_name>
    <description>Monoclonal antibody by IV infusion plus standard ART</description>
    <arm_group_label>UB-421(25mg/kg) Q2W add-on treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>UB-421(25 mg/kg) Q4W</intervention_name>
    <description>Monoclonal antibody by IV infusion plus standard ART</description>
    <arm_group_label>UB-421(25mg/kg) Q4W add-on treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV-1 sero-positive

          2. Male with body weight ≥ 50 kg or female with body weight ≥ 45 kg.

          3. HIV-1 plasma RNA level below 50 RNA copies/mL .

        Exclusion Criteria:

          1. Subjects with active systemic infections, except for HIV-1, that the Investigator
             feels the infections may confound evaluation and treatment for HIV-1.

          2. Current active hepatitis B carriers, ie, hepatitis B surface antigen positive.

          3. Current active hepatitis C carriers, ie, hepatitis C virus (HCV) antibody positive.

          4. History of anaphylaxis to other mAbs.

          5. Any vaccination within 8 weeks prior to the first dose of assigned drug.

          6. Use of immunomodulators, HIV vaccine, or systemic chemotherapy within 180 days prior
             to the first dose of assigned drug.

          7. Females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant
             during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Allen Tsai</last_name>
    <phone>+886-3-668-4800</phone>
    <phone_ext>3641</phone_ext>
    <email>allen.tsai@unitedbiopharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhonghao Shi</last_name>
    <phone>+886-3-668-4800</phone>
    <phone_ext>3204</phone_ext>
    <email>zhonghao.shi@unitedbiopharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allen Tsai</last_name>
      <email>allen.tsai@unitedbiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allen Tsai</last_name>
      <email>allen.tsai@unitedbiopharma.com</email>
    </contact>
    <investigator>
      <last_name>Hung-Chin Tsai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>201</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allen Tsai</last_name>
      <email>allen.tsai@unitedbiopharma.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>November 12, 2018</study_first_submitted>
  <study_first_submitted_qc>November 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2018</study_first_posted>
  <last_update_submitted>November 21, 2019</last_update_submitted>
  <last_update_submitted_qc>November 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

